From: Genetic Engineering & Biotechnology News <gen@genmail.co>
Date: April 15, 2025 at 11:13:00 AM GMT-3
To: mxh5000@gmail.com
Subject: LSD Analogue That May Have Potential for Treating Schizophrenia Developed
Reply-To: update@genmail.co

Plus more biotechnology news

View in browser TOP STORIES Tuesday, April 15, 2025      LSD Analog That May Have Potential for Treating Schizophrenia Developed Researchers developed a neuroplasticity-promoting drug that is a close structural analogue of LSD and harnesses the psychedelic’s therapeutic power, but which exhibits reduced hallucinogenic potential. + MORE   Newly Discovered Immune Cell Type Regulates Food Allergies Researchers from New York University (NYU) Langone Health have revealed that a special group of cells in the intestines, termed tolerogenic dendritic cells (tDC), reduce the immune responses caused by exposure to food proteins to prevent allergies.   + MORE   Lonza Joins Center for Continuous Manufacturing and Advanced Crystallization CMAC is an international research hub with a configuration of academic and industrial companies within applied and pre-competitive research programs, and translation to industry models. It aims to transform pharmaceutical manufacturing and crystallization processes. + MORE   In Vitro Human Models Grow Up Once thought improbable, in vitro human models are demonstrating technological prowess in a growing range of applications. + MORE   Cellino, Karis Bio Partner on Autologous iPSC-Based Therapy for Cardiovascular Disease The agreement allows the partners to use Cellino'a Nebula platform to scale the manufacturing of iPSC-derived stem cells for a regenerative therapy for cardiovascular disease. Karis Bio is currently testing the therapy in a clinical study in South Korea. + MORE   Cutting hPSC Production Time By 66% The ability to generate pure populations of endothelial cells without sorting increases scaling and reduces time and cost.This streamlines the process of using them for developing in vitro models or cell therapies that involve vascularization. + MORE   TOUCHING BASE PODCAST Discussing De-Extinction, Trump’s Tariffs Touch Biopharma, and Reports from Recent Travels Are Dire Wolves really back? GEN editors discuss the early impact of the Trump administration’s tariffs on biotech and the growing alarm in the scientific community in the wake of sweeping layoffs and leadership departures at the FDA, CDC, and NIH. + MORE   SPONSORED PIP-seq in Practice: Real-World Applications of Illumina’s New scRNA-Seq Technology Single-cell RNA sequencing has emerged as one of the most important technologies for studying the transcriptome of individual cells at high resolution. One of the key tools in this space, Illumina’s particle-templated instant partition sequencing (PIP-seq), is already helping to unlock the biology behind neurodegenerative disorders and other diseases. + MORE  UPCOMING The State of Multiomics & NGS In GEN's virtual summit, we proudly host a magnificent group of talented researchers from industry and academia. In addition, the summit will include breakout sessions from our sponsors and plenty of live audience discussion. + MORE   Effective mAb Aggregate Removal: Evaluating Three Key Chromatography Resins In this GEN webinar, Alejandro Becerra, PhD, will present results from using an IgG1 post-Protein A pool as a model system to evaluate the aggregate removal capabilities of three Thermo Fisher chromatography resins under typical operating conditions. + MORE   Genetic Engineering & Biotechnology News Mary Ann Liebert, Inc., a Sage Company 140 Huguenot Street  New Rochelle, NY 10801 You have received this email at mxh5000@gmail.com Unsubscribe        Manage Preferences